急性骨髄性白血病(AML)治療薬の世界市場

◆英語タイトル:Acute Myeloid Leukemia (AML) - Dynamic Market Forecast to 2026
◆商品コード:GDHC002FS
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年12月22日
◆ページ数:72
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD8,495 ⇒換算¥959,935見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD16,990 ⇒換算¥1,919,870見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD25,485 ⇒換算¥2,879,805見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Acute Myeloid Leukemia (AML) – Dynamic Market Forecast to 2026
Summary

Acute Myeloid Leukemia (AML) is a disease that has been characterized by a stagnant pipeline and, consequently, the treatment paradigm has not substantially changed over time. Since the 1970s, the standard of care in newly diagnosed fit patients has been a chemotherapy bases 7 + 3 induction regimen (seven days of cytarabine + three days of an anthracycline), aimed at achieving a complete hematologic remission (CR), followed by consolidation therapy with cytarabine, or an allogeneic hematopoietic cell transplantation (HCT). In the last decade, a better understanding of the molecular basis of AML has encouraged the development of new targeted therapies, and this led to the launch of the first targeted agents in 2017. The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the AML space, including regulatory, commercial, and clinical events as well as understand how all of these events will impact the projected market forecast.

Scope

Key events covered in the Dynamic Market Forecast include –
- Regulatory filings
- Approval decisions
- Pricing changes
- Patent litigation
- Clinical trial data announcements
- Clinical trial failures
- Clinical trial timeline updates

Components of the slide deck include –
- Timeline of market-impacting events
- Key clinical trial landscape updates
- Conference coverage
- Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective
- Overview of updates to the forecast model based on anticipated future impact of events
- Forward-looking events calendar listing expected key updates to the AML competitive space through December 2018

Reasons to buy

- Recent Regulatory Events
- Recent Commercial Events
- Recent Clinical Events
- New SOC expected for elderly t-AML and AML-MRC patients
- Adoption of the First FLT3 Inhibitor, Rydapt, in the US and EU
- Lack of Competition in the IDH+ AML Market Segment Benefits Celgene and Agios
- US Approval of the First CD33 Targeting Agent, Mylotarg

【レポートの目次】

Table of Contents
1. Dynamic Market Forecast Overview 6
1.1 Related Reports 7
1.2 Upcoming Related Reports 8
2. Executive Summary 9
2.1 Key Updates to AML Market Dynamics 10
2.2 Key Events in Update 11-12
2.3 Updates to Treatment Algorithms 13-14
2.4 Updates to Pipeline Competitive Assessment 15-16
2.4 Market Insight on Key Events 17
3. Conference Coverage – ASH 2017
3.1 Selected Abstracts ASH2017 – AML 19-20
4. Event 1: New SOC expected for elderly t-AML and AML-MRC patients
4.1 Key Updates to the Frontline Setting – Elderly Patients 22
4.2 Jazz, Vyxeos (CPX-351) 23-24
4.3 What Do Physicians Think? 25
4.4 Summary/Trends 26
4.5 Sources 27
5. Event 2: Adoption of the First FLT3 Inhibitor, Rydapt, in the US and EU
5.1 Key Updates About the Use of FLT3 Inhibitors in the First- Line Setting 29
5.2 Competitive Landscape of FLT3 Inhibitors in AML 30
5.3 Novartis, Rydapt (midostaurin) 31
5.4 What Do Physicians Think? 32
5.5 Arog, crenolanib 33
5.6 Astellas, gilteritinib 34
5.7 What Do Physicians Think? 35
5.8 Summary/Trends 36
5.9 Sources 37
6. Event 3: Lack of Competition in the IDH+ AML Market Segment Benefits Celgene and Agios
6.1 Key Updates in IDH+ AML 39
6.2 Agios/Celgene, Idhifa 40-41
6.3 Agios, ivosidenib 42-44
6.4 What Do Physicians Think? 45
6.5 Summary/Trends 46
6.6 Sources 47
7. Event 4: US Approval of the First CD33 Targeting Agent, Mylotarg
7.1 Key Updates on Mylotarg 49
7.2 Pfizer, Mylotarg (gemtuzumab ozogamicin) 50
7.3 What Do Physicians Think? 51
7.4 Additional Clinical Trial Updates- CD33+ 52
7.5 Summary/Trends 53
7.6 Sources 54
8. Additional Events
8.1 Takeda, pevonedistat 56
8.2 What Do Physicians Think? 57
9. Other Events of Interest
9.1 Various Developers 59
9.2 Sources 60
10. Events Calendar
10.1 Key Events Expected to Occur in 2018 62
11. Appendix
11.1 Methodology 64
11.2 Primary Research 65-66
11.3 About the Authors 67-69
11.4 About GlobalData 70
11.5 Contact Us 71
11.6 Disclaimer 72





【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[急性骨髄性白血病(AML)治療薬の世界市場]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆